XML 75 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated income statements - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Statement [line items]      
Net sales $ 50,545 $ 51,626 $ 48,659
Other revenues 1,283 1,251 1,239
Cost of goods sold (15,486) (15,867) (15,121)
Gross profit 36,342 37,010 34,777
Selling, general and administration (14,253) (14,886) (14,197)
Research and development (9,996) (9,540) (8,980)
Other income 805 1,852 1,742
Other expense (3,701) (2,747) (3,190)
Operating income 9,197 11,689 10,152
(Loss)/income from associated companies (9) 15,339 673
Interest expense (837) (811) (869)
Other financial income and expense 20 (80) (78)
Income before taxes 8,371 26,137 9,878
Income taxes (1,416) (2,119) (1,807)
Net income 6,955 24,018 8,071
Attributable to      
Shareholders of Novartis AG 6,955 24,021 8,072
Non-controlling interests $ 0 $ (3) $ (1)
Basic earnings per share [abstract]      
Basic earnings per share $ 3.19 $ 10.71 $ 3.55
Diluted earnings per share [abstract]      
Diluted earnings per share $ 3.17 $ 10.63 $ 3.52